{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "caption": "Cabotegravir effectiveness, overall and by subgroup",
                    "analysis": "ITT",
                    "endpoint": "primary",
                    "group": "TDF-FTC",
                    "events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR]",
                "outcomes": "[0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "caption": "Cabotegravir effectiveness, overall and by subgroup",
                    "analysis": "ITT",
                    "endpoint": "primary",
                    "group": "TDF-FTC",
                    "age group": "<25 years",
                    "events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "HR (95% CI)": "0.17 (0.05\u20130.54)"
                },
                "measures": "[HR]",
                "outcomes": "[0.17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "caption": "Cabotegravir effectiveness, overall and by subgroup",
                    "analysis": "ITT",
                    "endpoint": "primary",
                    "group": "TDF-FTC",
                    "age group": "\u226525 years",
                    "events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)"
                },
                "measures": "[HR]",
                "outcomes": "[0.09]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "caption": "Cabotegravir effectiveness, overall and by subgroup",
                    "analysis": "ITT",
                    "endpoint": "primary",
                    "group": "TDF-FTC",
                    "contraceptive method": "DMPA",
                    "events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)"
                },
                "measures": "[HR]",
                "outcomes": "[0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "caption": "Cabotegravir effectiveness, overall and by subgroup",
                    "analysis": "ITT",
                    "endpoint": "primary",
                    "group": "TDF-FTC",
                    "contraceptive method": "NET-EN",
                    "events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)"
                },
                "measures": "[HR]",
                "outcomes": "[0.22]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "caption": "Cabotegravir effectiveness, overall and by subgroup",
                    "analysis": "ITT",
                    "endpoint": "primary",
                    "group": "TDF-FTC",
                    "contraceptive method": "Implant",
                    "events per total PY in cabotegravir group": "0",
                    "events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)"
                },
                "measures": "[HR]",
                "outcomes": "[0.06]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "caption": "Cabotegravir effectiveness, overall and by subgroup",
                    "analysis": "ITT",
                    "endpoint": "primary",
                    "group": "TDF-FTC",
                    "contraceptive method": "Other",
                    "events per total PY in cabotegravir group": "0",
                    "events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)"
                },
                "measures": "[HR]",
                "outcomes": "[0.32]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "caption": "Cabotegravir effectiveness, overall and by subgroup",
                    "analysis": "ITT",
                    "endpoint": "primary",
                    "group": "TDF-FTC",
                    "BMI group": "\u226430 kg/m\u00b2",
                    "events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "HR (95% CI)": "0.16 (0.06\u20130.45)",
                    "p value": "0.47"
                },
                "measures": "[HR]",
                "outcomes": "[0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "caption": "Cabotegravir effectiveness, overall and by subgroup",
                    "analysis": "ITT",
                    "endpoint": "primary",
                    "group": "TDF-FTC",
                    "BMI group": ">30 kg/m\u00b2",
                    "events per total PY in cabotegravir group": "0",
                    "events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)"
                },
                "measures": "[HR]",
                "outcomes": "[0.05]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "yes"
        }
    ],
    "total_extracted_claims": 10,
    "total_ground_truth_claims": 9,
    "number_of_matches": 9
}